The authors concluded that in a diverse, community-based population with new systolic heart failure, spironolactone did not reduce death or hospitalization, but did increase the incidence of hyperkalemia.
A second sodium-glucose cotransporter 2 (sglt2) inhibitor has been approved for the treatment of adults with type 2 diabetes mellitus. These agents increase glucose secretion by inhibiting reabsorption in the kidney. Renal glucose threshold can be lowered to 70-90 mg/dL from a norm of 240 mg/dL in patients with diabetes. Dapagliflozin follows canagliflozin as the second SGLT2 approved and is marketed by Bristol-Myers Squibb and AstraZeneca as Farxiga.